Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UL68
UPID:
MYT1L_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UL68; A7E2C7; B2RP54; Q6IQ17; Q9UPP6
Background:
Myelin transcription factor 1-like protein, encoded by the gene with accession number Q9UL68, is pivotal in neuronal differentiation. It represses non-neuronal genes during neuron differentiation and negative regulators of neurogenesis, such as the Notch signaling pathway. This protein's unique ability to repress multiple differentiation programs underscores its significance in neurodevelopment.
Therapeutic significance:
Linked to Intellectual developmental disorder, autosomal dominant 39, Myelin transcription factor 1-like protein's understanding could pave the way for innovative therapeutic strategies targeting neurodevelopmental disorders.